This inventor holds 1 USPTO granted patent, plus 2 CIPO patents and 1 EPO patent. Top assignee: Janssen Pharmaceutica Nv. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: The Innovations of Benjamin C. Harman
Introduction
Benjamin C. Harman is an accomplished inventor based in Oaklyn, NJ (US). He is known for his significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting cancer.
Latest Patents
Harman holds a patent for "CD123 binding agents and uses thereof." This patent includes antibodies that specifically bind to CD123, along with related polynucleotides capable of encoding these antibodies or their antigen-binding fragments. The patent also describes methods for using these antibodies in diagnosing, treating, or monitoring CD123-expressing cancer. This innovation has the potential to aid in determining treatment options for patients afflicted with CD123-expressing cancer.
Career Highlights
Harman is currently associated with Janssen Pharmaceutica NV, a leading pharmaceutical company. His work focuses on developing innovative solutions for cancer treatment, showcasing his commitment to advancing medical science.
Collaborations
Harman collaborates with notable colleagues, including Francois Gaudet and Jennifer F. Nemeth. These partnerships enhance the research and development efforts within his field.
Conclusion
Benjamin C. Harman's contributions to biotechnology, particularly through his patent on CD123 binding agents, highlight his role as a key innovator in cancer treatment. His work continues to impact the medical community positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile